Divis Laboratories Ltd Analyst Rating
based on 26 analysts
33.33%
Buy
22.22%
Hold
44.44%
Sell
Based on 26 analysts offering long term price targets for Divis Laboratories Ltd. An average target of ₹4668.46
Source: S&P Global Market Intelligence
Divis Laboratories Ltd Share analysis
Divis Laboratories Ltd price forecast by 26 analysts
Downside of
High
₹6850
Target
₹4668.46
Low
₹3000
Divis Laboratories Ltd target price ₹4668.46, a slight downside of -20.87% compared to current price of ₹5810.7. According to 26 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Divis Laboratories Ltd revenue growth forecast
Expected growth rate Q1, FY2026:35.79%
Forecast
Actual
Including amortisation and stock based compensations
Divis Laboratories Ltd EPS growth forecast
EPS estimate Q1, FY2026:62.21%
Forecast
Actual
Source: S&P Global Market Intelligence
Divis Laboratories Ltd Performance
Day's Low
Day's High
₹5,782.05₹5,949.8552 Week's Low
52 Week's High
₹3,350₹6,275.85
| Returns % | |
| 1 Month Return | -5.07 % |
| 3 Month Return | + 20.63 % |
| 1 Year Return | + 67.76 % |
| Market Stats | |
| Previous Close | ₹5,899.95 |
| Open | ₹5,915.00 |
| Volume | 4.33L |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹1,56,625.13Cr |
Divis Laboratories Ltd Key Statistics
| P/E Ratio | 85.32 |
| PEG Ratio | 4.5 |
| Market Cap | ₹1,56,625.13 Cr |
| P/B Ratio | 6.75 |
| EPS | 60.38 |
| Dividend Yield | 0.87 |
| Sector | Pharmaceuticals |
| ROE | 12.04 |
Divis Laboratories Ltd Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| HOLD | ₹1,56,625.13 Cr | 50.55% | 0.50 | ₹1,600 Cr | ₹7,845 Cr | |
| BUY | ₹1,06,661.37 Cr | 51.12% | 0.67 | ₹1,656 Cr | ₹10,727 Cr | |
| HOLD | ₹41,864.92 Cr | 7.17% | 0.58 | ₹1,297 Cr | ₹14,755 Cr | |
| HOLD | ₹29,953.51 Cr | -0.02% | 0.50 | ₹772 Cr | ₹5,664 Cr | |
| BUY | ₹1,25,403.42 Cr | 49.34% | 0.50 | ₹4,155 Cr | ₹25,774 Cr |
Divis Laboratories Ltd Mutual Fund Holdings
About Divis Laboratories Ltd
Divis Laboratories Ltd's top products include APIs and intermediates for anti-infectives, cardiovascular, central nervous system, anti-diabetics, gastro-intestinal and anti-inflammatory treatments. The company is also a leader in the manufacture of custom synthesis and process development services for the global pharmaceutical industry.
Divis Laboratories Ltd is the proud owner of several popular brands, including Divis Life, Divis Pharma and Divis Health. Divis Life offers a range of health and wellness products, while Divis Pharma provides a wide range of APIs, intermediates and custom synthesis services.
Share Price: ₹5810.70 per share as on 12 Nov, 2024 04:01 PM
Market Capitalisation: ₹1,56,625.13Cr as of today
Revenue: ₹2,338.00Cr as on September 2024 (Q3 24)
Net Profit: ₹510.00Cr as on September 2024 (Q3 24)
Listing date: 12 Mar, 2003
Chairperson Name: Ramesh B V Nimmagadda
| Organisation | Divis Laboratories Ltd |
| Headquarters | Hyderabad |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Key events for Divis Laboratories Ltd
Divis Laboratories Reports Strong Financial Growth - 12 Nov, 2024
Divis Laboratories reported a 17% y-o-y revenue increase to Rs. 2,238 crore, with PAT rising 47% y-o-y to Rs. 510 crore. Despite slight EBITDA decline, the overall financial metrics indicate strong growth potential. Sharekhan maintains a BUY rating with a target price of Rs. 6,812.
Divis Laboratories Reports Strong Q2 Results and Outlook - 11 Nov, 2024
Divis Laboratories posted a robust Q2 FY25 with a net profit of ₹510 crore, up 46.5% YoY. Revenue increased by 22.5% to ₹2,338 crore, driven by custom synthesis growth. Analysts maintain positive outlook with target price revisions, reflecting strong performance and future growth potential.
Divis Laboratories Reports Strong Q2 Performance - 10 Nov, 2024
Divis Laboratories posted a 47% increase in net profit to ₹510 crore and a 22.5% revenue rise to ₹2,338 crore, driven by custom synthesis demand. The company plans to invest ₹1,600 crore in FY25, focusing on the Kakinada project set to begin production in December 2024.
Divis Laboratories Reports Strong Q2 Earnings Growth - 09 Nov, 2024
Divis Laboratories announced impressive Q2 FY25 results, with revenue rising 22.47% to ₹2,338 crore and net profit increasing 46.55% to ₹510 crore, surpassing estimates.
Divis Labs Anticipates Strong Q2 Financial Results - 07 Nov, 2024
Divis Laboratories is projected to show significant growth in its Q2FY25 results, with a 36% increase in net profit and a 15% rise in revenue, driven by strong performance in the API and CSM segments.
Concerns Raised Over Marine Pollution by Pharma Companies - 04 Nov, 2024
Fisherfolk have raised alarms about untreated water released by Aurobindo and Divis Laboratories into the Bay of Bengal, claiming it threatens the marine ecosystem.
Divis Laboratories Faces Pressure After Court Ruling - 15 Oct, 2024
Divis Laboratories' stock fell 1.7% after a US court allowed generic competition for Entresto, its largest revenue source. Analysts predict a potential 10% EPS decline by FY27 due to early market entry of generics.
Divis Labs Gains Analyst Confidence Amid Nifty Exit - 14 Oct, 2024
Divis Laboratories sees increased buy calls and improved growth outlook, particularly in GLP-1 APIs, despite its exit from the Nifty 50 index. Citi re-initiates coverage with a buy rating, highlighting significant revenue potential, while some brokerages remain cautious due to reliance on a single growth trigger.
Insights on Divis Laboratories Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTBest in 1 Year
In the last 1 year, DIVISLAB has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
- POSITIVE IMPACT
FII Holding Up
Foreign Institutions have increased holdings from 16.16% to 17.25% in Sep 2024 quarter
- POSITIVE IMPACT
Price Rise
In the last 6 months, DIVISLAB stock has moved up by 50.8%
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 2 quarters, 430.0 Cr → 510.0 Cr (in ₹), with an average increase of 15.7% per quarter
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 2 quarters, 2.19K Cr → 2.44K Cr (in ₹), with an average increase of 10.1% per quarter
NO EFFECTAgainst Peers
In the last 3 years, Torrent Pharmaceuticals Ltd has given 125.8% return, outperforming this stock by 104.0%
NEGATIVE IMPACTMF Holding Down
Mutual Funds have decreased holdings from 13.10% to 11.92% in Sep 2024 quarter
- NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 10.18% to 9.80% in Sep 2024 quarter
- NEGATIVE IMPACT
Promoter Holding Down
Promoters have decreased holdings from 51.90% to 51.89% in Sep 2024 quarter
News
Divis Laboratories Share Price Today Up 3%
Real-time updates on Divis Laboratories share price. Check out the detailed analysis of the company in this live blog.29 Jul, 2024 05:30 PMTrent and BEL could join Nifty in September rejig; LTIM, Divi's Likely to exit
Tata Group's Trent and Bharat Electronics were poised to join the Nifty 50 index during the September reshuffle, as predicted by IDBI Capital. Trent's shares increased 84% and Bharat Electronics rose 68% this year. LTI Mindtree and Divi's Laboratories were likely to be excluded. The index review is based on semi-annual market data, effective from September 30.31 Jul, 2024 07:39 AMPrice Updates: Divis Laboratories Hits New 52-Week High at Rs 4953.20, Registers 0.61% Increase
Discover the Divi's Laboratories Stock Liveblog, your go-to destination for real-time updates and comprehensive analysis of a top-performing stock. Keep track of Divi's Laboratories's latest details, including: Last traded price 4944.25, Market capitalization: 130695.49, Volume: 19961, Price-to-earnings ratio 81.68, Earnings per share 60.27. Our liveblog offers a holistic view of Divi's Laboratories by examining both fundamental and technical indicators. Stay ahead of market trends with breakingnews that can impact Divi's Laboratories's performance. Our market analysis and expert opinions provide valuable insights to guide your investment decisions. Join us on the Divi's Laboratories Stock Liveblog and stay informed in this dynamic market landscape. The data points are updated as on 01-08-2024 09:20 IST01 Aug, 2024 08:33 AMDivis Laboratories Ltd Financials
Index Inclusions
Divis Laboratories Ltd Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 51.89% | ||
| Foreign Institutions | 17.25% | 6.77 | |
| Mutual Funds | 11.92% | ||
| Retail Investors | 9.8% | ||
| Others | 9.14% | 5.47 |
Divis Laboratories Ltd Key Indicators
Divis Laboratories Ltd Valuation
Divis Laboratories Ltd in the last 5 years
Lowest (28.97x)
November 21, 2022
Industry (56.74x)
November 11, 2024
Today (85.32x)
November 11, 2024
Highest (89.87x)
October 14, 2024
Divis Laboratories Ltd Earnings and Dividends
Divis Laboratories Ltd Earnings Results
Divis Laboratories Ltd’s net profit jumped 46.55% since last year same period to ₹510Cr in the Q2 2024-2025. On a quarterly growth basis, Divis Laboratories Ltd has generated 18.6% jump in its net profits since last 3-months.
Read More about Earnings ResultsDivis Laboratories Ltd Dividends May,2024
In the quarter ending March 2024, Divis Laboratories Ltd has declared dividend of ₹30 - translating a dividend yield of 0.52%.
Read More about Dividends
Divis Laboratories Ltd Technicals Summary
Bearish
Neutral
Bullish
Divis Laboratories Ltd is currently in a Bearish trading position according to technical analysis indicators.
FAQs on Divis Laboratories Ltd
- Get a PAN card.
- Open a Demat account.
- Open a Trading account.
- Link your Demat account to your Trading account.
- Fund your Trading account.
- Place an order to buy Divis Laboratories Ltd shares.
Divis Laboratories Ltd (DIVISLAB) share price today is ₹5810.7
Divis Laboratories Ltd is listed on NSE
Divis Laboratories Ltd is listed on BSE
- Today’s highest price of Divis Laboratories Ltd is ₹5949.85.
- Today’s lowest price of Divis Laboratories Ltd is ₹5782.05.
PE Ratio of Divis Laboratories Ltd is 85.32
PE ratio = Divis Laboratories Ltd Market price per share / Divis Laboratories Ltd Earnings per share
Today’s traded volume of Divis Laboratories Ltd(DIVISLAB) is 4.33L.
Today’s market capitalisation of Divis Laboratories Ltd(DIVISLAB) is ₹156625.13Cr.
| Divis Laboratories Ltd(DIVISLAB | Price |
|---|---|
52 Week High | ₹6275.85 |
52 Week Low | ₹3350 |
Divis Laboratories Ltd(DIVISLAB) share price is ₹5810.7. It is down -7.41% from its 52 Week High price of ₹6275.85
Divis Laboratories Ltd(DIVISLAB) share price is ₹5810.7. It is up 73.45% from its 52 Week Low price of ₹3350
| Divis Laboratories Ltd(DIVISLAB | Returns |
|---|---|
1 Day Returns | -89.25% |
1 Month Returns | -5.07% |
3 Month Returns | 20.63% |
1 Year Returns | 67.76% |